Carregant...
The Potential of Harnessing IL-2-Mediated Immunosuppression to Prevent Pathogenic B Cell Responses
Immunosuppressive drugs can partially control Antibody (Ab)-dependent pathology. However, these therapeutic regimens must be maintained for the patient’s lifetime, which is often associated with severe side effects. As research advances, our understanding of the cellular and molecular mechanisms und...
Guardat en:
| Publicat a: | Front Immunol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8112607/ https://ncbi.nlm.nih.gov/pubmed/33986755 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.667342 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|